HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma (HCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Peng Wang) · peng_wang@fudan.edu.cn · +86021-64041990

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Philadelphia, United States

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Wuhan, China

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China